ACTU (Actuate Therapeutics) Short-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Short-Term Debt?

Actuate Therapeutics's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

Actuate Therapeutics's quarterly Short-Term Debt increased from Mar. 2024 ($5.00 Mil) to Jun. 2024 ($6.90 Mil) but then declined from Jun. 2024 ($6.90 Mil) to Sep. 2024 ($0.00 Mil).

Actuate Therapeutics Short-Term Debt Historical Data

The historical data trend for Actuate Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Short-Term Debt Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

Short-Term Debt

Actuate Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial			-	-	5.00	6.90	-

Actuate Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Actuate Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3?, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.